-
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Wednesday, July 29, 2020 - 11:30am | 1009Read More...Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...
-
Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay
Thursday, April 23, 2020 - 3:49pm | 785Read More...Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's investigational drug aducanumab will be delayed. The Biogen Analysts Barclays analyst Carter Gould maintained an Overweight rating on Biogen...
-
UBS Upgrades Gilead, Sees EPS Upside In 2019
Wednesday, April 10, 2019 - 11:17am | 400Read More...It’s been a rough couple of years for Gilead Sciences, Inc. (NASDAQ: GILD) investors, with the stock down more than 30 percent since early 2016. One analyst said Wednesday that Gilead may finally be turning the corner this year. The Analyst UBS analyst Carter Gould upgraded Gilead...
-
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Friday, March 22, 2019 - 1:30pm | 595Read More...Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...
-
UBS: Buy Biogen For Pipeline, M&A Potential
Wednesday, January 31, 2018 - 10:29am | 377Read More...Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside. The Rating UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410. The Thesis Biogen’s...
-
UBS Loses Conviction In Spark Therapeutics, Downgrades
Tuesday, December 12, 2017 - 3:49pm | 484Read More...Spark Therapeutics Inc (NASDAQ: ONCE) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. The Analyst UBS' Carter Gould downgraded Spark's stock rating from Buy to Neutral with a price target slashed from $92 to...
-
Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure
Friday, October 20, 2017 - 2:14pm | 611Read More...Celgene Corporation (NASDAQ: CELG) stock plummeted 10 percent Friday after the company reported that its testing of GED-0301 for treatment of Crohn’s disease has failed to meet its efficacy targets. A handful of Wall Street analysts weighed in on Celgene stock following the news. Here’s...
-
UBS Cuts Price Target On Celgene To $146 As GED Drops Out
Friday, October 20, 2017 - 8:51am | 288Read More...The discontinuation of Celgene Corporation (NASDAQ: CELG)’s mongerson for Crohn’s disease prompted a 6.6-percent sell-off in Friday’s premarket trading. But UBS was undeterred by the announcement. “Looking forward, we are still encouraged by the prospects for this next...
-
'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts
Wednesday, July 26, 2017 - 4:33pm | 622Read More...Amgen, Inc. (NASDAQ: AMGN) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst M. Ian Somaiya downgraded Amgen's stock rating from Outperform to Market Perform...
-
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
Wednesday, July 26, 2017 - 10:09am | 350Read More...Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...
-
The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It
Monday, June 19, 2017 - 3:16pm | 364Read More...While risks to the stock still remain, UBS has upgraded Biogen Inc (NASDAQ: BIIB) from Sell to Neutral and has raised its price target for the stock from $262 to $270. At this point, the risks are fully priced into the stock, analyst Carter Gould wrote on Monday. “In our view, the competitive...
-
Analysts Confident In Acceleron Pharma's Drug Trial Outcomes
Thursday, June 23, 2016 - 1:30pm | 374Read More...Barclays reiterated its Overweight rating on Acceleron Pharma Inc (NASDAQ: XLRN) after a meeting with management reinforced key elements of the firm's thesis on the company, particularly regarding the drug Luspatercept. Luspatercept And Acceleron's Recent Performance Acceleron's lead...
-
Acceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects
Monday, June 13, 2016 - 4:38pm | 218Read More...Acceleron Pharma Inc (NASDAQ: XLRN) presented the longer-term Phase 2 data for luspatercept in MDS and beta-thal at the EHA meeting in Copenhagen. Barclays' Carter Gould maintained an Overweight rating on the company, while raising the price target to $42. “Data across both...
